Amylin as a Future Obesity Treatment
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Obesity is defined as abnormal or excessive fat accumulation that contributes to detrimental health impacts. One-third of the population suffers from obesity, and it is important to consider obesity as a chronic disease requiring chronic treatment. Amylin is co-secreted with insulin from β pancreatic cells upon nutrient delivery to the small intestine as a satiety signal, acts upon sub-cortical homeostatic and hedonic brain regions, slows gastric emptying, and suppresses post-prandial glucagon responses to meals. Therefore, new pharmacological amylin analogues can be used as potential anti-obesity medications in individuals who are overweight or obese. In this narrative review, we analyse the efficacy, potency, and safety of amylin analogues. The synthetic amylin analogue pramlintide is an approved treatment for diabetes mellitus which promotes better glycaemic control and small but significant weight loss. AM833 (cagrilintide), an investigational novel long-acting acylated amylin analogue, acts as a non-selective amylin receptor. This calcitonin G protein-coupled receptor agonist can serve as an attractive novel treatment for obesity, resulting in reduction of food intake and significant weight loss in a dose-dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Amylin is co-secreted with insulin from pancreatic β-cells in response to food intake, delays gastric emptying, inhibits glucagon secretion, improves glycaemia, increases satiety, and reduces food intake without decreasing energy expenditure (appendix p 6), [146][147][148] with a mode of action that differs from GLP-1.149”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [148]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“As WL with GLP-1 RA and amylin analogues results both from distinct and overlapping pathways, a combination of these entero-pancreatic hormones may induce a synergistic WL effect [84].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [84]
In the citing paper
“It slows down the gastric emptying and inhibits the glucagon secretion – both these actions improve glycemia [60].”
In the citing paper
“Amylin is a pancreatic hormone secreted by β-cells in response to food intake.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Obesity Stigma: Important Considerations for Public Health
Puhl, R. M., & Heuer, C. A. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.159491 · Cited by 1,917
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Mechanisms underlying weight loss after bariatric surgery
Miras, A. D., & le Roux, C. W. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.119 · Cited by 344
Self-citationEnebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316 · cited 1×
“…104.7± 19.2 106.9± 22.1 108.1± 17.2 104.0± 17.8 43.0± 11.0 46.0± 12.0 45.0± 14.0 44.0± 14.0 44.0± 12.0 46.0± 13.0 47.0± 12.0 73 71 72 75 71 73 73 Yes Yes Yes Yes Yes Yes NA Enebo et al. (2021)14 20 Randomized, placebo controlled 0.16 mg cagrilintide+2.4 mg semaglutide 0.30 mg cagrilintide+2.4…”
InfluentialLau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01751-7 · Cited by 278 · cited 1×
“…14.3 103.2± 17.8 49.9± 9.0 51.0± 8.0 50 50 Yes NA Aronne et al. (2007)30 16 Double-blind, placebo controlled 240 µg tid Placebo 137 67 37.9± 5.7 37.6± 5.5 105.5± 18.4 104.9± 19.1 48.0± 10.0 19.0± 10.0 80 81 Yes NA Lau et al. (2021)15 26 Double-blind, placebo controlled 0.3 mg cagrilintide once…”
InfluentialSelf-citationAmylin Agonists: A Novel Approach in the Treatment of Diabetes
Schmitz, O., Brock, B., & Rungby, J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s233 · Cited by 239
Lutz, T., Mollet, A., Rushing, P., Riediger, T., & Scharrer, E. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801664 · Cited by 223
Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment.
Ogawa, A., Harris, V, McCorkle, S. K., Unger, R. H., & Luskey, K. L. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114528 · Cited by 205
Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 1×
“…18.0 55.0± 10.0 55.0± 9.0 48 54 Yes NA Smith et al. (2007)29 6 Double-blind, placebo controlled 180 µg before meals Placebo 60 28 35.3± 3.6 36.3± 4.7 100.2± 14.3 103.2± 17.8 49.9± 9.0 51.0± 8.0 50 50 Yes NA Aronne et al. (2007)30 16 Double-blind, placebo controlled 240 µg tid Placebo 137…”
InfluentialThe role of amylin in the control of energy homeostasis
Lutz, T. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00703.2009 · Cited by 175
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Food Intake and Eating Behavior After Bariatric Surgery
Al-Najim, W., Docherty, N. G., & le Roux, C. W. (2018) · Physiological Reviews · doi:10.1152/physrev.00021.2017 · Cited by 173
Self-citationSmith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care · doi:10.2337/dc08-0029 · Cited by 172 · cited 1×
“Significant loss in body weight vs. placebo Smith et al. (2008)12 16 Double-blind, placebo controlled 120 µg pramlintide bid 240 µg pramlintide bid 360 µg pramlintide bid 120 µg pramlintide tid 240 µg pramlintide tid 360 µg pramlintide tid Placebo 38 38 32 45 49 42 36 37.5± 5.0 37.7± 5.1 38.1± 5.4…”
MethodInfluentialInfusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats.
Mollet, A., Gilg, S., Riediger, T., & Lutz, T. (2004) · Physiology and Behavior · doi:10.1016/j.physbeh.2004.01.006 · Cited by 151
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Smith, S. R., Blundell, J. E., Burns, C., Ellero, C., Schroeder, B. E., Kesty, N. C., Chen, K. S., Halseth, A. E., Lush, C. W., & Weyer, C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00217.2007 · Cited by 130 · cited 1×
“…No No Yes Yes Yes NA Riddle et al. (2007)28 16 Double-blind, placebo controlled 120 µg pramlintide bid or tid Placebo 107 105 35.0± 6.0 35.0± 5.0 103.0± 18.0 103.0± 18.0 55.0± 10.0 55.0± 9.0 48 54 Yes NA Smith et al. (2007)29 6 Double-blind, placebo controlled 180 µg before meals Placebo 60…”
InfluentialPurnell, J. Q., & Weyer, C. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302010-00004 · Cited by 128
Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., & Kolterman, O. (2007) · Diabetes Care · doi:10.2337/dc07-0589 · Cited by 116
Hoogwerf, B. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1978 · Cited by 87
GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01537.x · Cited by 74
Boccia, L., Gamakharia, S., Coester, B., Whiting, L., Lutz, T. A., & Le Foll, C. (2020) · Peptides · doi:10.1016/j.peptides.2020.170366 · Cited by 70
Amylin-mediated control of glycemia, energy balance, and cognition
Mietlicki‐Baase, E. G. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.034 · Cited by 68
Amylin Selectively Signals Onto POMC Neurons in the Arcuate Nucleus of the Hypothalamus
Lutz, T. A., Coester, B., Whiting, L., Dunn-Meynell, A. A., Boyle, C. N., Bouret, S. G., Levin, B. E., & Le Foll, C. (2018) · Diabetes · doi:10.2337/db17-1347 · Cited by 68
Fletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D., et al. (2021) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000567 · Cited by 68
Amylin activates distributed CNS nuclei to control energy balance
Mietlicki-Baase, E. G., & Hayes, M. R. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.01.013 · Cited by 66
Bello, N. T., Kemm, M. H., Ofeldt, E. M., & Moran, T. H. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00275.2010 · Cited by 66
Colburn, W. A., Gottlieb, A. B., Koda, J., & Kolterman, O. G. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04147.x · Cited by 60
Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?
Qiu, W. Q., & Zhu, H. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00186 · Cited by 55
Control of food intake and energy expenditure by amylin—therapeutic implications
Lutz, T. A. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.13 · Cited by 54
Qiao, Y.-C., Ling, W., Pan, Y.-H., Chen, Y.-L., Zhou, D., Huang, Y.-M., Zhang, X.-X., & Zhao, H.-L. (2017) · Oncotarget · doi:10.18632/oncotarget.16008 · Cited by 54
Züger, D., Forster, K., Lutz, T. A., & Riediger, T. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.02.006 · Cited by 40
Herrmann, K., Frias, J. P., Edelman, S. V., Lutz, K., Shan, K., Chen, S., Maggs, D., & Kolterman, O. G. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2635 · Cited by 25
Herrmann, K., Zhou, M., Wang, A., & de Bruin, T. W. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0030-z · Cited by 21
Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
Hoogwerf, B. J. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.5.477 · Cited by 18
A novel GPR55-mediated satiety signal in the oval Bed Nucleus of the Stria Terminalis
Hawken, E. R., Normandeau, C. P., Gregory, J. G., Cécyre, B., Bouchard, J., Mackie, K., & Dumont, É. C. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0309-0 · Cited by 10 · cited 1×
“Baseline characteristics of trials included in this review Study Study duration, Hawken et al. (2019)17 Blinding Study arm Number of patients randomized BMI (kg/m2) Body weight (kg) Age (yr), Hawken et al. (2019)17 Female (”
Cited by
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85].”
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
“129 It functions as a satiety signal, acting upon brain regions involved in both homeostatic and hedonic appetite regulation; it also slows the gastric emptying, and thereby suppresses post-prandial glucagon responses to meals.”
Background
Metadata
- Authors
- Dehestani, B., Stratford, N. R., & Roux, C. W. L.
- Affiliations
- University College Dublin (IE)
- Corresponding author
- Dehestani, Babak
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2021-12-30
- Volume
- 30
- Issue
- 4
- Pages
- 320-325
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC8735818
- OpenAlex
- W4200574551
- Cited by
- 72
- References
- 38
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 16 · 2023: 12 · 2022: 5
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- amylin, amylin analogues, obesity treatment, pramlintide, cagrilintide, amylin receptor, satiety, gastric emptying, weight loss, dietary intake, anti-obesity drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.